Navigation Links
American Biotech Labs(R) Obtains FDA Approval for New Wound Care Gel Product
Date:4/14/2009

Company's innovative new ASAP Wound Dressing Gel is now approved "for the topical management of minor cuts, lacerations, abrasions, 1st and 2nd degree burns, and skin irritations"

SALT LAKE CITY, April 14 /PRNewswire/ -- American Biotech Labs, LLC (ABL), developer of a new class of products based on the company's patented nano-catalytic SilverSol Technology(R), today announced that the company has been granted formal approval by the U.S. Food and Drug Administration (FDA) to market its ASAP Wound Dressing Gel throughout the United States.

The FDA approval letter confirms that ABL may market ASAP Wound Dressing Gel "for the topical management of minor cuts, lacerations, abrasions, 1st and 2nd degree burns, and skin irritations." The product utilizes ABL's innovative SilverSol Technology, which has garnered multiple patents in the U.S. and several countries throughout the world, including a broad-use patent that provides the company with exclusive rights to use its silver-based products to combat many of the world's most destructive pathogens, including malaria, tuberculosis, MRSA and HIV.

"We are delighted with the FDA's decision to grant approval for ABL to broadly market our ASAP Wound Dressing Gel," said Dr. William Moeller, a managing director of American Biotech Labs. "We feel this is a singularly effective wound care product, and it is a tremendous validation for us that ABL products have now received approval from the FDA as well as from the EPA."

ABL has performed extensive anti-microbial studies against bacteria, yeast, fungus and other pathogens. Information about these studies is available at research section of the ABL Website, www.americanbiotechlabs.com/researchprotected/researchmenu.html.

About American Biotech Labs

American Biotech Labs (ABL; www.americanbiotechlabs.com), founded in 1998, utilizes patented processes and SilverSol Technology(R) to create singularly powerful and effective nano-catalytic silver products. In extensive testing performed by a variety of respected laboratories and researchers, ABL's silver hydrosol has consistently demonstrated the ability, without any known toxic side effects, to destroy a wide range of bacteria, viruses, yeast, and molds. ABL products have been approved by the by the Environmental Protection Agency (EPA) as a disinfectant for dental water lines, and as a surface disinfectant for bacteria, yeast and mold in hospital, residential, commercial and industrial settings; and by the U.S. Food and Drug Administration (FDA) for wound care. The company's products have been the subject of multiple peer-reviewed articles in professional journals, and are sold worldwide at health food stores and by medical professionals under the Silver Biotics(R) and ASAP Solution(R) brands, and through a variety of private labels.

    Press Contact:

    Kimball Thomson
    Next Phase Communications (for American Biotech Labs)
    kthomson@npcomm.com
    801.918.3637


'/>"/>
SOURCE American Biotech Labs, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. American Legacy Foundation(R) and Georgetown University Medical Center Create Research Collaboration
2. The American Federation for Medical Research Unites Top Leaders to Mitigate U.S. Crisis in Clinical Research
3. While majority of Americans express interest in organ and tissue donation, few register
4. Thousands of Americans Sign Living Wills on Thursday April 16
5. Blue Cross and Blue Shield of Minnesota and American Well(TM) Join to Bring Online Care to Minnesota
6. New Low-Cost Handheld Device offers Independence for Millions of Visually Impaired Americans
7. American College of Pediatricians: Another Blow to Childrens Rights
8. Humanitas Approved by American Psychological Association (APA) as Provider of Continuing Education Credits to Psychologists
9. Wiley-Blackwell and the American Heart Association present new book series
10. Sodexo Named as One of the Top Three Companies for African Americans on 2009 DiversityInc Top Ten Companies List
11. HITSP to Address Provisions of American Recovery and Reinvestment Act
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... 2017 , ... Award-winning medical group Allied Anesthesia today announced ... chair for Orange County health care system CalOptima Friday. CalOptima announced its election ... Mark Refowitz’s term, which runs through June 30 of this year, until another ...
(Date:3/28/2017)... Appleton, WI (PRWEB) , ... March 28, 2017 ... ... how self-funded health plans work, the Self-Funding Success website has recently developed and ... about Self-Funded Health Plans ” was created based on common inquiries the site’s ...
(Date:3/28/2017)... ... March 28, 2017 , ... Prominant bariatric surgeon ... is thrilled to offer the recently FDA-approved Obalon Balloon System to his patients. ... SkyLex Advanced Surgical’s already comprehensive list of weight-loss services. Dr. Liu is ...
(Date:3/28/2017)... ... , ... Oily skin is a common and unwelcomed occurrence in people of all ages, genders ... offer to the discussion of dealing with excess skin oil. “Oily skin is a challenge ... that can help remove the oily shine while keeping the skin fresh and clean,” says ...
(Date:3/27/2017)... , ... March 27, 2017 , ... New patients who ... for leading sleep apnea treatment, with or without a referral. Sleep apnea is often ... can include daytime sleepiness, morning headaches and chronic snoring. , Dr. Braasch seeks ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... Calif. , March 27, 2017  Impax Laboratories, ... has appointed Paul M. Bisaro as Impax,s ... the Company,s Board, effective March 27, 2017. Mr. Bisaro ... served as Interim President and Chief Executive Officer since ... of generic and branded pharmaceutical experience, Mr. Bisaro, 56, ...
(Date:3/27/2017)... Genprex, Inc. , a privately held, clinical-stage biopharmaceutical company developing immunogene ... Chief Operating Officer, is scheduled to present a corporate overview at ... Cancer BioPartnering & Investment Forum: Tuesday, March 28, 2017 at 3:00 ... ... Future Leaders in Biotech Industry – Friday, April 7, 2017 at ...
(Date:3/24/2017)... 2017 Research and Markets has announced ... report to their offering. ... The Cell Therapy Manufacturing Market, 2017-2027 ... of cell therapy manufacturing and focuses both on contract manufacturers ... are anticipated to emerge as viable alternatives to conventional treatment ...
Breaking Medicine Technology: